Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Myo-Inositol-Hexasulphate is a synthetic, highly sulfated derivative of myo-inositol, structurally related to inositol phosphates such as inositol hexaphosphate (IP6/phytic acid). It is a small molecule with the formula C6H12O24S6 and a molecular weight of approximately 660.5 g/mol[3][6]. While naturally occurring in plants and mammalian cells as phosphorylated forms (notably IP6), the sulfated form is primarily experimental. The compound acts as a strong chelator of minerals and may influence cellular signaling pathways by mimicking or interfering with endogenous inositols. There are no approved therapeutic indications for this compound; it has not advanced beyond experimental status[3]. Its mechanism of action likely involves modulation of cellular processes through interaction with proteins that bind poly-anionic molecules, but specific pharmacological targets have not been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-Myo-Inositol-Hexasulphate.